Cargando…

Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin

BACKGROUND: For many indications, BoNT/A is repetitively injected with the risk of developing neutralizing antibodies (NABs). Therefore, it is important to analyze whether there is a difference in antigenicity between the different licensed BoNT/A preparations. METHODS: In this cross-sectional study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hefter, Harald, Rosenthal, Dietmar, Jansen, Alexander, Brauns, Raphaela, Ürer, Beyza, Bigalke, Hans, Hartung, Hans-Peter, Meuth, Sven G., Lee, John-Ih, Albrecht, Philipp, Samadzadeh, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886600/ https://www.ncbi.nlm.nih.gov/pubmed/36195775 http://dx.doi.org/10.1007/s00415-022-11395-2

Ejemplares similares

No Secondary Treatment Failure during Incobotulinumtoxin—A Long-Term Treatment Demonstrated by the Drawing of Disease Severity
por: Hefter, Harald, et al.
Publicado: (2023)

Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study
por: Hefter, Harald, et al.
Publicado: (2020)

Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure
por: Hefter, Harald, et al.
Publicado: (2022)

The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2022)

Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature
por: Samadzadeh, Sara, et al.
Publicado: (2020)

Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study
por: Hefter, Harald, et al.
Publicado: (2023)

The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany
por: Samadzadeh, Sara, et al.
Publicado: (2021)

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
por: Hefter, Harald, et al.
Publicado: (2021)

The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
por: Samadzadeh, Sara, et al.
Publicado: (2020)

Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2019)

“Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study
por: Hefter, Harald, et al.
Publicado: (2023)

Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
por: Hefter, Harald, et al.
Publicado: (2021)

Pseudocholinesterase as a Biomarker for Untreated Wilson’s Disease
por: Hefter, Harald, et al.
Publicado: (2022)

Differences in the Time Course of Recovery from Brain and Liver Dysfunction in Conventional Long-Term Treatment of Wilson Disease
por: Hefter, Harald, et al.
Publicado: (2023)

Long‐term adherence and response to botulinum toxin in different indications
por: Lee, John‐Ih, et al.
Publicado: (2020)

Comparing soleus injections and gastrocnemius injections of botulinum toxin for treating adult spastic foot drop: a monocentric observational study
por: Hefter, Harald, et al.
Publicado: (2021)

Mildly Impaired Foot Control in Long-Term Treated Patients with Wilson’s Disease
por: Samadzadeh, Sara, et al.
Publicado: (2021)

Analysis of Running in Wilson’s Disease
por: Samadzadeh, Sara, et al.
Publicado: (2022)

Enhanced Effect of Botulinum Toxin A Injections into the Extensor Digitorum Brevis Muscle after Local Mechanical Leg Vibration: A Case Report
por: Hefter, Harald, et al.
Publicado: (2021)

Analysis of Single-Leg Hopping in Long-Term Treated Patients with Neurological Wilson’s Disease: A Controlled Pilot Study
por: Hefter, Harald, et al.
Publicado: (2022)

The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia
por: Hefter, Harald, et al.
Publicado: (2021)

The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation—A Monocentric Cross-Sectional Pilot Study
por: Hefter, Harald, et al.
Publicado: (2022)

Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®))
por: Dressler, Dirk, et al.
Publicado: (2013)

Cholinesterase Deficiency Syndrome—A Pitfall in the Use of Butyrylcholinesterase as a Biomarker for Wilson’s Disease
por: Arslan, Max, et al.
Publicado: (2022)

Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats
por: Feng, Ya, et al.
Publicado: (2017)

Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II
por: Kent, Ruth, et al.
Publicado: (2021)

AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2018)

OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays
por: Rupp, David, et al.
Publicado: (2020)

Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson’s Disease: Six Cases and Literature Review
por: Hefter, Harald, et al.
Publicado: (2021)

The Necessity of a Locally Active Antidote in the Clinical Practice of Botulinum Neurotoxin Therapy: Short Communication
por: Hefter, Harald, et al.
Publicado: (2022)

Exploring the Interplay between the Clinical and Presumed Effect of Botulinum Injections for Cervical Dystonia: A Pilot Study
por: Hefter, Harald, et al.
Publicado: (2023)

Real-World Six-Year National Cost-Minimization Analysis of IncobotulinumtoxinA and OnabotulinumtoxinA in the VA/DoD Healthcare Systems
por: Kazerooni, Rashid, et al.
Publicado: (2021)

Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins—a single cohort 4-year follow-up study
por: Hefter, Harald, et al.
Publicado: (2012)

Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study
por: Rappl, Thomas, et al.
Publicado: (2013)

Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA
por: Hefter, Harald, et al.
Publicado: (2020)

Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis
por: Hefter, Harald, et al.
Publicado: (2013)

The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2020)

Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy
por: Hefter, Harald, et al.
Publicado: (2020)

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2019)

Different Response Behavior to Therapeutic Approaches in Homozygotic Wilson’s Disease Twins with Clinical Phenotypic Variability: Case Report and Literature Review
por: Samadzadeh, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9ud3itbcoc72dpb66314rl83ed